MyLeukemiaTeam

Targeted therapy drugs for Acute Lymphoblastic Leukemia (ALL) with the Philadelphia chromosome (Ph+) include:

- Imatinib (Gleevec)
- Dasatinib (Sprycel)
- Nilotinib (Tasigna)
- Ponatinib (Iclusig)
- Bosutinib (Bosulif)

These drugs are tyrosine kinase inhibitors (TKIs) that target the BCR-ABL protein caused by the Philadelphia Show Full Answer

Targeted therapy drugs for Acute Lymphoblastic Leukemia (ALL) with the Philadelphia chromosome (Ph+) include:

- Imatinib (Gleevec)
- Dasatinib (Sprycel)
- Nilotinib (Tasigna)
- Ponatinib (Iclusig)
- Bosutinib (Bosulif)

These drugs are tyrosine kinase inhibitors (TKIs) that target the BCR-ABL protein caused by the Philadelphia chromosome. They are often used in combination with chemotherapy and tend to cause fewer side effects than traditional treatments.

For personal experiences and tips, you can join the MyLeukemiaTeam community to ask questions and share stories with others who understand life with leukemia.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

The Benefits of Targeted Therapy for Leukemia | MyLeukemiaTeam

Treatments for Leukemia | MyLeukemiaTeam